Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lisata Therapeutics, Inc.
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
August 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
July 16, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
July 10, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
May 08, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
May 02, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
April 23, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
April 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
April 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
March 21, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
February 22, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Present at BIO CEO & Investor Conference
February 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
January 17, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
January 04, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
December 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Present at NobleCon19 Investor Conference
November 28, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
November 09, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
October 26, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
October 24, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
October 17, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
September 28, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Participation in InfoSec World 2023
September 20, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
September 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
September 06, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.